Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

NASDAQ:BPTH opened at $0.18 on Friday. The firm has a 50-day moving average of $0.77 and a two-hundred day moving average of $0.90. Bio-Path has a 1-year low of $0.12 and a 1-year high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.